#STDWeek: Drug-resistant Gonorrhea Testing

Pilot program increases access to drug-resistant gonorrhea testing in two states

Drug-resistant Gonorrhea Testing Piloted in Emergency Departments

During STD Awareness Week, it’s important to remember that drug-resistant gonorrhea is an urgent public health threat. Gonorrhea has quickly developed resistance to all but one class of antibiotics, and half of all infections are resistant to at least one antibiotic—leading to more than an estimated half a million drug-resistant gonorrhea infections in the United States each year.  To increase access to resistance testing, CDC partnered with health departments in North Carolina and Indiana to pilot drug-resistant gonorrhea surveillance beyond traditional sexually transmitted infection (STI) clinics and into emergency departments, where more people are seeking STI care. Find out what they accomplished and learned together in only a year’s time.

As drug-resistant gonorrhea continues to jeopardize treatment options in the U.S., CDC’s AR Solutions Initiative will continue investing in programs like the AR Lab Network and the Strengthening the United States Response to Resistant Gonorrhea (SURRG) program to better position the U.S. to prevent and control this threat.

Centers for Disease Control and Prevention 1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348 Questions or Problems  |  Unsubscribe